They have pretty specific timelines - I don’t know, possibly some questions, but there is also a timeline for that.
Maybe a different pathway on Ph2 Janssen data ie CDx? My bet is on DeNovo as well, as PromarkerD has utility beyond being a companion diagnostic with Canagliflozin.
Be good to get news on FDA advice soon.
BTW what is with a “No Deal Roadshow”? I am invested in multiple biotechs and have never seen that term used before - I find it a bit bizarre the need to include that term in an ASX ANN. Why not just “Investor Presentation Roadshow”?
GLTAH
Ann: Study shows diabetes drug improves PromarkerD risk scores, page-44
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.0¢ |
Change
0.010(1.27%) |
Mkt cap ! $104.8M | |||
| Open | High | Low | Value | Volume |
| 81.0¢ | 83.5¢ | 78.5¢ | $274.7K | 338.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 412 | 79.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.5¢ | 3774 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |